In Vivo CAR-T for Liver Cancer Reaches Patients in China: GPC3 mRNA Program + Walvax Manufacturing Deal
CellOrigin is testing mRNA-LNP 'in vivo CAR' therapy for liver cancer — T cells programmed inside the body, not in a lab. GPC3 target, Walvax manufacturing deal, first patients already dosed in 2026.
Read Article →